Ambagon Therapeutics Is A Biotechnology Company Based In Eindhovennetherlandsdedicated To Developing Small Molecule Cancer Drugsfounded In 2022The Company Focuses On Targeting Oncogenic Proteins By Stabilizing Protein Protein Interactionsutilizing Its Proprietary Molecular Glue Platformambagon S Leadership Team Comprises Experts In 14 3 3 Protein Biology And Structural Drug Discoveryemphasizing Innovation In The Biotech Field The Company S Core Technology Revolves Around 14 3 3 Proteinswhich Play A Crucial Role In Regulating Cellular Processesambagon S Small Molecules Aim To Stabilize Interactions Between These Proteins And Client Proteinsincluding Transcription Factors And Oncoproteinsto Restore Tumor Suppression Mechanismswhile Specific Drug Candidates Are Not Detailedambagon S Pipeline Is Centered On Oncologywith Potential Applications In Metabolicneurodegenerativeand Infectious Diseasesthe Company Is Committed To Expanding The Druggable Proteome And Developing Therapeutic Candidates For High Need Oncology Indications
